Skip to content

Announcing FastFinder Genotyper, a new way of performing high-throughput end-point PCR

Thomas Beuls | Press Release | 30/09/2018

HASSELT, BELGIUM & BOSTON, MA, US – 28/09/18 | UgenTec today announced a new end-point PCR analysis software called FastFinder Genotyper. FastFinder Genotyper uses artificial intelligence (AI) methods to significantly accelerate genotyping analysis workflows and improve data interpretation in applications such as agricultural breeding programs.  

The software will be deployed in high-throughput environments and will be designed to increase the speed of processing the typical clusters generated by end-point PCR. Software currently available for end-point PCR offers oversimplified cluster analysis methods and requires extensive human intervention, forcing laboratories to spend lots of eyes-on time on their data, losing valuable expert time and running studies with suboptimal efficiency.

UgenTec is currently evaluating FastFinder Genotyper with VHL Genetics, a service company with three leading laboratories based in the Netherlands, Belgium and Germany, headquartered in Wageningen (the Netherlands). VHL uses end-point PCR for its breeding programs as well as its seed and animal quality control workflows.

“Globally, billions of end-point PCR tests are performed each year, mainly in plant & seed environments.” says Tom Martens, CCO at UgenTec. “FastFinder Genotyper will drastically reduce manual analysis time for experts and standardize the analysis of end-point PCR.”

“It’s exciting to add a new product to our PCR software portfolio” says Steven Verhoeven, CEO at UgenTec. “FastFinder Genotyper perfectly fits our mission to bring the latest of artificial intelligence & software technologies to laboratories across the globe, with applications ranging from infectious disease over oncology to ensuring success in breeding programs and food quality and safety.”

UgenTec’s FastFinder currently enables well over 100 laboratories worldwide to save up to 90% of analysis time while increasing standardization for real-time PCR based diagnostics.

Boston, San Francisco, Stockholm – January 12, 2023